Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy
- PMID: 34693571
- DOI: 10.1002/adma.202107434
Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy
Abstract
Nanomedicines have the potential to provide advanced therapeutic strategies in combating tumors. Polymer-prodrug-based nanomedicines are particularly attractive in cancer therapies owing to the maximum drug loading, prolonged blood circulation, and reduced premature leakage and side effects in comparison with conventional nanomaterials. However, the difficulty in precisely tuning the composition and drug loading of polymer-drug conjugates leads to batch-to-batch variations of the prodrugs, thus significantly restricting their clinical translation. Polyprodrug nanomedicines inherit the numerous intrinsic advantages of polymer-drug conjugates and exhibit well-controlled composition and drug loading via direct polymerization of therapeutic monomers, representing a promising nanomedicine for clinical tumor therapies. In this review, recent advances in the development of polyprodrug nanomedicines are summarized for tumor elimination. Various types of polyprodrug nanomedicines and the corresponding properties are first summarized. The unique advantages of polyprodrug nanomedicines and their key roles in various tumor therapies are further highlighted. Finally, current challenges and the perspectives on future research of polyprodrug nanomedicines are discussed.
Keywords: cancer therapy; drug delivery; nanomedicine; polyprodrug; self-assembly.
© 2021 Wiley-VCH GmbH.
References
-
- R. K. Jain, T. Stylianopoulos, Nat. Rev. Clin. Oncol. 2010, 7, 653.
-
- B. Y. S. Kim, J. T. Rutka, W. C. W. Chan, N. Engl. J. Med. 2010, 363, 2434.
-
- T. Lammers, S. Aime, W. E. Hennink, G. Storm, F. Kiessling, Acc. Chem. Res. 2011, 44, 1029.
-
- J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat. Rev. Cancer 2017, 17, 20.
-
- A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J. Controlled Release 2015, 200, 138.
Publication types
MeSH terms
Substances
Grants and funding
- 2021Z99CFZ007/Tsinghua University Spring Breeze Fund
- NUHSRO/2020/133/Startup/08/Startup Funding from Tsinghua University
- NUHSRO/2021/034/TRP/09/Nanomedicine/NUS School of Medicine Nanomedicine Translational Research Programme
- NUHSRO/2021/044/Kickstart/09/LOA/NUS School of Medicine Kickstart Initiative
- 0121/ 2018/A3/Science and Technology Development Fund
- 0007/2020/A/Science and Technology Development Fund
- MYRG2017-00010-ICMS/University of Macau
- MYRG2019-00059-ICMS/University of Macau
- 21871301/National Natural Science Foundation of China
- 22071275/National Natural Science Foundation of China
- 51973038/National Natural Science Foundation of China
- 91963107/National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources
Medical
